Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Study results comparing REVLIMID regimen to stem cell transplant in multiple myeloma patients

Celgene International Sàrl announced clinical data from an investigational study of patients with multiple myeloma who were younger than 65 years old and received either REVLIMID (lenalidomide), melphalan and prednisone (MPR) or melphalan plus autologous stem cell transplant (MEL200) following an induction treatment of REVLIMID plus low-dose dexamethasone (Rd) were presented during the 51st American Society of Hematology’s annual meeting in New Orleans, LA.

8 Dec 2009

Potentially promising data from Phase I/II study of elotuzumab presented at ASH 2009

Facet Biotech Corporation and Bristol-Myers Squibb Company announced that potentially promising data from a Phase I/II study of elotuzumab, an investigational humanized antibody being studied for the treatment of relapsed multiple myeloma (MM), were presented today at the American Society of Hematology (ASH) 2009 Annual Meeting in New Orleans.

8 Dec 2009

Data from two phase Ib clinical trials of dacetuzumab for DLBCL reported

Seattle Genetics, Inc. today reported data from two phase Ib clinical trials of dacetuzumab, one in combination with Rituxan® (rituximab) and Gemzar® (gemcitabine) for diffuse large B-cell lymphoma (DLBCL), and the other in combination with Revlimid® (lenalidomide) for multiple myeloma.

8 Dec 2009

Carfilzomib shows noteworthy responses and low side effects among multiple myeloma patients

The second-generation proteasome inhibitor carfilzomib is showing noteworthy response rates and low levels of adverse side effects among multiple myeloma patients in a phase II clinical trial, researchers reported today at the 51st Annual Meeting of the American Society of Hematology.

8 Dec 2009

Results from CytRx's Phase 2 STAR-1 registration clinical trial for tamibarotene announced

ytRx Corporation, a biopharmaceutical company, today announced favorable preliminary results from its Phase 2 STAR-1 registration clinical trial for tamibarotene in the treatment of acute promyelocytic leukemia (APL) in patients failing other treatments.

7 Dec 2009

Study data of Perifosine + Bortezomib combination in multiple myeloma patients presented

Æterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that its partner Keryx Biopharmaceuticals Inc. reported updated efficacy and safety data as well as new survival data on the clinical activity of perifosine (KRX-0401) in combination with bortezomib (Velcade(R)) (+/- dexamethasone) in patients with relapsed/refractory multiple myeloma.

7 Dec 2009

Preclinical and Phase I data for TG-0054 presented by TaiGen Biotechnology

TaiGen Biotechnology Co., Ltd. announced today the presentation of Phase I and preclinical data for TG-0054, the Company's chemokine receptor CXCR4 antagonist and a novel, potent stem cell mobilizer, at the ASH Annual Meeting held in New Orleans, the US, from December 5 to 8, 2009.

7 Dec 2009

Presentation of preclinical data demonstrating the combination of ISTODAX and Velcade announced

Gloucester Pharmaceuticals announced today the presentation of preclinical data demonstrating that the combination of ISTODAX® (romidepsin) and Velcade® (bortezomib) resulted in synergistic anti-tumor activity in B-cell non-Hodgkin's lymphoma cell lines.

7 Dec 2009

New three-drug combination may be effective for treating patients with bone cancer

A new three-drug combination has shown in a phase 1/2 clinical trial that it is a "highly effective regimen" in the treatment of patients newly diagnosed with multiple myeloma, a cancer of white blood cells in bone marrow, say researchers from Dana-Farber Cancer Institute.

7 Dec 2009

Researchers explore optimal induction therapies for managing blood cancer

There have been significant scientific advances in the field of blood cancers, and leading experts continue to gain a better understanding of how certain diseases progress in order to discover new treatment options and provide patients with the best care.

7 Dec 2009

VELCADE based regimens are cost-effective for payers and patients, finds study

Millennium: The Takeda Oncology Company today announced that two studies presented at the 51st American Society of Hematology (ASH) Annual Meeting found that VELCADE based regimens are more cost-effective for payers and reduced out-of-pocket costs for patients than other commonly used multiple myeloma treatments.

7 Dec 2009

Updated safety data from Phase 2b 003-A1 study of carfilzomib announced

Onyx Pharmaceuticals, Inc. today announced updated safety data from the pivotal Phase 2b 003-A1 study, known as the 003 trial, demonstrating that carfilzomib is well-tolerated in heavily pre-treated relapsed and refractory multiple myeloma patients.

7 Dec 2009

ImmunoGen reports encouraging clinical data of IMGN901

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, today reported encouraging clinical data with its IMGN901 product candidate in the treatment of relapsed and relapsed/refractory multiple myeloma (MM), including prolonged benefit in patients whose disease had progressed on multiple prior treatment regimens.

6 Dec 2009

Bortezomib can improve control of GVHD and immune system recovery

A drug that has become a mainstay of multiple myeloma treatment may outperform alternative therapies in re-establishing the immune system of patients who have received stem cell transplants from unrelated, partially matched donors, according to early clinical trial results to be presented by Dana-Farber Cancer Institute investigators at the American Society of Hematology's (ASH) annual meeting on Sunday, Dec. 6 (Abstract 48, Ernest N. Morial Convention Center, Room 243-245, 5:45 pm CT).

6 Dec 2009

Dana-Farber Cancer Institute receives 2009 MMRC Center of the Year Award

The Multiple Myeloma Research Consortium (MMRC) today announced that it has awarded the Dana-Farber Cancer Institute, and its clinical researchers, Kenneth Anderson, MD, and Paul Richardson, MD, with the 2009 MMRC Center of the Year Award.

5 Dec 2009

IMF to stage presentation on multiple myeloma at ASH annual meeting

The International Myeloma Foundation (IMF)—supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians—today said presentations at the annual meeting of the American Society of Hematology (ASH) will cover all stages of multiple myeloma, a major milestone in treating this and related cancers.

4 Dec 2009

Cancer patient “Statement of Principles” brought to the 2009 ASH meeting

A coalition of cancer patient advocacy organizations led by the International Myeloma Foundation (IMF) and the MDS Foundation (MDSF), will bring its cancer patient “Statement of Principles” to the 2009 Meeting of the American Society of Hematology (ASH) in New Orleans December 5th through 8th.

4 Dec 2009

Financial aspects of cancer treatment reduces compliance

New data being released today by the Association of Oncology Social Work (AOSW) demonstrate the extraordinary financial hardships that often complicate or compromise a patient’s battle against cancer. Sixty-three percent of oncology social workers surveyed said that financial issues reduce patients’ compliance with their cancer treatment – even though that treatment is key to their recovery. Forty percent of patients reported depleting their savings, while almost 30% reported dealing with bill collectors.

3 Dec 2009

Medical research experts explore new strategies to speed up treatments for medical disorders

Nearly 600 medical research executives, scientists, policy makers, and funders today convened to explore novel development approaches and innovative funding strategies at the inaugural Partnering for Cures meeting.

3 Dec 2009

ImmunoCellular Therapeutics options immunotherapy targeting CSCs using abnormal Notch and Numb pathways

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is focused on the development of novel immune-based cancer therapies, announced today that it has entered into an option agreement with The University of Texas M. D. Anderson Cancer Center relating to an immunotherapy targeting cancer stem cells (CSCs) which has demonstrated in pre-clinical animal models significant abilities to target and destroy CSCs.

3 Dec 2009

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Study results comparing REVLIMID regimen to stem cell transplant in multiple myeloma patients

Potentially promising data from Phase I/II study of elotuzumab presented at ASH 2009

Data from two phase Ib clinical trials of dacetuzumab for DLBCL reported

Carfilzomib shows noteworthy responses and low side effects among multiple myeloma patients

Results from CytRx's Phase 2 STAR-1 registration clinical trial for tamibarotene announced

Study data of Perifosine + Bortezomib combination in multiple myeloma patients presented

Preclinical and Phase I data for TG-0054 presented by TaiGen Biotechnology

Presentation of preclinical data demonstrating the combination of ISTODAX and Velcade announced

New three-drug combination may be effective for treating patients with bone cancer

Researchers explore optimal induction therapies for managing blood cancer

VELCADE based regimens are cost-effective for payers and patients, finds study

Updated safety data from Phase 2b 003-A1 study of carfilzomib announced

ImmunoGen reports encouraging clinical data of IMGN901

Bortezomib can improve control of GVHD and immune system recovery

Dana-Farber Cancer Institute receives 2009 MMRC Center of the Year Award

IMF to stage presentation on multiple myeloma at ASH annual meeting

Cancer patient “Statement of Principles” brought to the 2009 ASH meeting

Financial aspects of cancer treatment reduces compliance

Medical research experts explore new strategies to speed up treatments for medical disorders

ImmunoCellular Therapeutics options immunotherapy targeting CSCs using abnormal Notch and Numb pathways

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in